Fostroxacitabine bralpamide (MIV-818)
Hepatocellular Carcinoma (HCC)
About Medivir
Medivir is a publicly traded, clinical-stage oncology company with a legacy in antiviral drug discovery, most notably contributing to the hepatitis C therapy simeprevir. The company has successfully pivoted to focus exclusively on cancer, applying its proprietary platforms to develop novel therapies for hard-to-treat tumors. Its strategy centers on advancing its lead asset, fostroxacitabine bralpamide, in liver cancer while expanding its pipeline through targeted discovery and partnerships. Medivir's mission is to deliver innovative treatments where current options are limited or non-existent.
View full company profileAbout Medivir
Medivir is a publicly traded, clinical-stage oncology company with a legacy in antiviral drug discovery, most notably contributing to the hepatitis C therapy simeprevir. The company has successfully pivoted to focus exclusively on cancer, applying its proprietary platforms to develop novel therapies for hard-to-treat tumors. Its strategy centers on advancing its lead asset, fostroxacitabine bralpamide, in liver cancer while expanding its pipeline through targeted discovery and partnerships. Medivir's mission is to deliver innovative treatments where current options are limited or non-existent.
View full company profileTherapeutic Areas
Other Hepatocellular Carcinoma (HCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 2/3 |
| Nelitolimod (SD-101) via PEDD™ + systemic checkpoint inhibitors | TriSalus Life Sciences | Phase 1/2 |
| YntraDose | BetaGlue Therapeutics | Pre-clinical |
| seRNA 001 | SRTD biotech | Preclinical |
| Seravue® (Diagnostic Assay) | ImCare Biotech | Development |
| BC3402 + IMFINZI | BioCity Biopharma | Phase 1b/2 |
| ZW251 | Zymeworks | Phase 1 |
| TTI-101 | Tvardi Therapeutics | Phase 1b/2 |